Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
JUPITER, Fla. - Biotechnology company Dyadic International, Inc. (NASDAQ:DYAI), currently valued at $31.2 million, announced today the appointment of Joe Hazelton as its new President, effective immediately. Hazelton, who retains his role as Chief Operating Officer, will spearhead the company’s strategic shift toward commercializing ancillary recombinant protein products for various markets, including life sciences, nutrition, and industrial uses. According to InvestingPro data, the company has demonstrated strong revenue growth of 57.6% over the last twelve months, though it remains in investment phase with negative earnings.
The company’s Board of Directors, which supports this strategic direction, has endorsed Hazelton’s appointment. This move aligns with Dyadic’s focus on immediate commercialization opportunities in high-growth areas such as cell culture media, DNA/RNA technologies, and non-animal food and nutrition ingredients. The company maintains a healthy financial position with a current ratio of 3.98, indicating strong liquidity to support its growth initiatives. InvestingPro analysis reveals several additional key metrics and insights available to subscribers, including detailed Fair Value assessments and growth projections.
Dyadic’s recent commercial validations include a partnership with Proliant Health and Biologicals for recombinant human albumin, collaboration with a non-animal dairy enzyme company, and a joint venture with Fermbox Bio, culminating in the launch of EN3ZYME and a significant purchase order in the cellulosic enzyme market.
Mark Emalfarb, Dyadic’s Founder and CEO, expressed confidence in the company’s strategic pivot and the validation of its approach through these partnerships. Emalfarb will continue to oversee the development of the company’s biopharmaceutical programs, focusing on funding, intellectual property strategy, and legacy projects.
Hazelton’s new role will involve scaling Dyadic’s scientific and commercial initiatives, deepening industry partnerships, and ensuring efficient execution of the company’s business strategy. His experience includes over two decades of leadership in biotech commercialization, with a proven track record at Dyadic and previously at Novartis.
Dyadic’s C1 and Dapibus™ platforms remain central to its strategy, offering differentiated, large-scale, high-titer production of recombinant proteins across targeted non-therapeutic markets. The company maintains a secondary focus on human and animal vaccines and therapeutics.
The information in this article is based on a press release statement from Dyadic International, Inc.
In other recent news, Dyadic International Inc. reported its financial results for the first quarter of 2025. The company disclosed a net loss of $0.07 per share, aligning with analyst expectations, while revenue slightly missed projections at $393,570 compared to the forecasted $394,000. Despite the minor revenue shortfall, Dyadic’s revenue increased from $335,000 in the same quarter last year, largely driven by grant revenue from the Gates Foundation and CEPI. The company is strategically shifting its focus towards non-pharmaceutical product launches, including recombinant human serum albumin, expected in the third quarter of 2025, and dairy enzymes by the end of the year. Dyadic has also reduced its number of paid collaborators from nine to four, signaling a strategic pivot toward commercialization. The company continues to explore revenue opportunities through partnerships with FirmBox and ProLiant. Notably, Dyadic is advancing its proprietary C1 and DAPIVIS platforms, which offer advantages in speed, scalability, and cost efficiency. These developments reflect Dyadic’s ongoing transition from a development-stage biotech firm to a product-driven enterprise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.